About GLP-1 Stocks
The first platform to combine FDA decisions, clinical trials, state laws, news, stock prices, and earnings — every angle of the GLP-1 industry, in one place.
Facts only
Aggregated, sourced, current. No commentary, no predictions, no recommendations. AI structures every record. Humans review when context matters.
All sources, one place
GLP-1 is the biggest pharmaceutical category in a generation. The information about it is scattered — buried in FDA bulletins, ClinicalTrials.gov databases, SEC filings, state legislative trackers, and dozens of news outlets. No single source pulls it together. This does.
Published as data lands
Every approval, every readout, every law, every earnings beat, every press release — automatically aggregated, structured, and published the moment the source data lands.
Data sources
Where the data comes from.
Every source. Every catalyst dated and linked. Refreshed automatically.
ClinicalTrials.gov — National Institutes of Health (NIH).
Trial registrations, status changes, and milestone updates for GLP-1 receptor agonist studies. Pulled daily. Trial records go back to 2000; backfill underway to cover the full registry depth for GLP-1-relevant studies.
openFDA — US Food and Drug Administration.
Drug label changes, new approvals, recalls, shortage notices, and enforcement actions for GLP-1 brand and generic names. Pulled daily. Coverage extends back to the 1990s; full historical backfill is in progress.
Congress.gov — US Congress (Library of Congress).
Federal bills referred to Energy & Commerce, Ways & Means, HELP, or Finance committees and matched against a GLP-1, obesity, drug-pricing, and compounding keyword list. Pulled twice daily. Federal bills go back to Congress 103 (1993); a 17-Congress backfill is in progress.
OpenStates — Plural Policy / nonprofit civic-data project.
State-level bills. What we poll and what we store are two different numbers. The fetch loop walks all 50 states plus DC and five US territories — 56 jurisdictions — round-robin, a few per run, daily. A jurisdiction only reaches the table below once one of its bills matches the keyword list and its legislature has published structured data to OpenStates. Stored coverage today is 10 states, not 56, and it widens as the loop keeps walking.
GNews — news aggregator.
English-language news coverage of GLP-1 industry companies and topics. Pulled daily. Free-tier depth is the trailing 12 months; deeper history is paywalled at the source.
Finnhub — financial data provider.
Stock quotes (every 15 minutes during US market hours), company news (every four hours), and earnings reports (weekly) for the tracked GLP-1 companies. Free tier depth for company news is the trailing year.
Live row counts
| Source | Coverage | Refresh cadence | Total records |
|---|---|---|---|
| FDA drug eventsopenFDA API | … | Every 24 hours | … |
| Clinical trialsClinicalTrials.gov | … | Every 24 hours | … |
| Congress billsCongress.gov | … | Twice daily | … |
| State billsOpenStates | … | Intermittent — see note | … |
| Industry newsFinnhub | … | Every 4 hours | … |
| General newsGNews | … | Every 24 hours | … |
| EarningsFinnhub | … | Weekly | … |
| Stock quotesFinnhub | … | Every 15 min during market hours | live |
All data comes from public APIs and government databases. We don't pay for proprietary feeds. Methodology details — dedup logic, auto-publish architecture, clinical-trial date mapping — are documented on the Methodology page.
Who built this
GLP-1 Stocks is built and operated by GLP-1 Studio LLC, a media production platform founded by Amanda Bonello — ACE Certified Health Coach, patient advocate, founder of the GLP-1 Collective Nonprofit.
GLP-1 Studio's other work includes The GLP-1 Studio Podcast, ranked in the top 10% globally, and a body of patient advocacy covered by major outlets including Politico, USA Today, CNBC, WIRED, and Fast Company.
Get in touch
For press, partnerships, API access, refunds, or legal matters, please use the contact form. We handle business and account inquiries there, and we do not answer platform how-to questions or GLP-1 medical questions.